This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.
Recombinant albumin IDELVION is formed by fusing recombinant albumin, known for its long half-life and low risk for immunogenic reaction, with recombinant Factor IX (rFIX).
Cleavable peptide linker Upon initiation of the coagulation cascade, recombinant albumin is cleaved, only releasing activated Factor IX (FIX) when needed for coagulation.
rFIX The rFIX remains linked to the recombinant albumin via a cleavable peptide linker so it remains inactive until it’s needed to control a bleed.
Recombinant albumin IDELVION is formed by fusing recombinant albumin, known for its long half-life and low risk for immunogenic reaction, with recombinant Factor IX (rFIX).
Cleavable peptide linker Upon initiation of the coagulation cascade, recombinant albumin is cleaved, only releasing activated Factor IX (FIX) when needed for coagulation.
rFIX The rFIX remains linked to the recombinant albumin via a cleavable peptide linker so it remains inactive until it’s needed to control a bleed.
IDELVION is the only extended half-life Factor IX therapy to deliver a zero median annualized spontaneous bleeding rate when dosed at 7 or 14 days in clinical trials
VIEW EFFICACY DATA
